BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Cell and gene therapies are revolutionizing healthcare\, offer
 ing promising solutions from curative treatments to long-term remission r
 ates. As these treatments enter the market\, ensuring fair access while a
 ddressing coverage and payment complexities becomes paramount.\n\nIntrodu
 cing the inaugural Cell and Gene Therapy Pricing and Reimbursement Summit
 . Biotech\, pharma\, physicians\, healthcare providers\, and regulatory a
 nd government agencies will unite to address key issues such as the impac
 t of regulatory acts\, implementing pricing models\, and collaborating on
  enhanced reimbursement strategies\, aiming to expedite the availability 
 of these advanced therapies to patients.\n\nWith the recent approval of C
 asgevy by Vertex Pharmaceuticals and CRISPR Therapeutics\, and Lyfgenia b
 y bluebird bio\; significant strides in healthcare have been made\, offer
 ing groundbreaking treatments with transformative potential\, yet present
 ing substantial cost challenges. The Inflation Reduction Act and new Cell
  and Gene Therapy (CGT) Access Model aim to address these cost concerns b
 y proposing innovative pricing models and reimbursement strategies to ens
 ure affordability and widespread access to these life-changing therapies.
 \n\nJoin us this June to discuss the impacts of this legislation and toge
 ther\, we will optimize patient access and propel the success of commerci
 al cell and gene therapy launches.\n\nURLs:Tickets: https://go.evvnt.com/
 2238529-2?pid=185Brochure: https://go.evvnt.com/2238529-3?pid=185\n\nTime
 : 8:00 AM - 4:15 PM\n\nSpeakers: Amar Kelkar\, Stem Cell Transplantation 
 Physician\, Instructor in Medicine\, Dana-Farber Cancer Institute\, Carlo
 s Martin\, Chief Commercial Officer and Head of International\, Rocket Ph
 arma\, Frank Zhang\, Head Of Commercial\, uniQure\, Jeff Chaffin\, Market
  Access Strategy Leader\, Novan Inc.\, Jie Zhang\, Vice President\, Globa
 l Value and Access\, Cell and Gene\, Novartis\, Kristin Wolff\, Vice Pres
 ident\, Market Access\, bluebird bio\, Laura Okpala. Executive Director\,
  US Reimbursement Policy\, Gilead Sciences\, Manpreet Sidhu\, Executive D
 irector\, Global Health Economics\, Outcomes Research and Epidemiology\, 
 Ultragenyx\, Marianne Hamilton Lopez\, Senior Research Director\, Biomedi
 cal Innovation\, Duke-Margolis Center for Health Policy\, Mark Trusheim\,
  Strategic Director\, NEWDIGS\, Tufts Medical Center\, Matt Feshbach\, Fo
 under and Chief Executive Officer\, AMBROSE Cell Therapy\, Phung Osborn V
 ice President of Market Access\, Orca Bio\, Robert Rouse\, Head Of Market
  Access\, CSL Behring\, Sumeet Panjabi\, Senior Director\, Real World Val
 ue and Evidence\, Janssen Pharmaceutical Companies of Johnson and Johnson
 \, Terry Cothran\, Senior Pharmacy Director\, Oklahoma Health Care Author
 ity\, Erica Cischke Vice President\, Government Affairs\, Alliance for Re
 generative Medicine\, Jesse Lemberger Sr. Director\, US Strategic Pricing
 \, Pfizer\n
DTEND:20240627T161500
DTSTAMP:20260512T225909Z
DTSTART:20240625T080000
LOCATION:Washington Marriott Capitol Hill\, 175\, L Street Northeast\, Was
 hington\, District of Columbia\, 20002\,
SEQUENCE:0
SUMMARY:Cell and gene therapies are revolutionizing healthcare\, offering 
 promising solutions from curative treatments to long-term remission rates
 . As thes...
UID:33990789-16ad-46df-a18e-84690342816a
END:VEVENT
END:VCALENDAR